U.S. FDA Investigation Of Ranbaxy Exposes Lax Drug Regulation In India
This article was originally published in PharmAsia News
Questions raised by the U.S. FDA about whether Ranbaxy Laboratories manufactures generics made from bulk drugs obtained from unapproved sources exposes lax regulatory oversight in undeveloped countries. India's regulatory standards are "abysmal," says an article in the Economic Times, with offenses often unreported or unpunished. The country has no credible way of monitoring adverse drug reactions, so the danger of sub-standard drugs in India is barely recognized, the newspaper said, despite the presence of more than 80 plants that have U.S. FDA approval. India has more than 20,000 other manufacturing units. (Click here for more
You may also be interested in...
Mayo Clinic announces AI-based partnerships with Google and voice-analysis company Vocalis Health this week.
US pharmacy group says that 10 to 12 states have indicated through an informal survey that they do not have the manpower or funding to implement the US FDA’s final MOU on inordinate compounding. They say what is at stake in these states is patient access to compounded medicines.
Ai Biomed’s PTeye helps to identify parathyroid tissue during thyroid surgery. Medtronic ENT also announced the FDA clearance of its NIM Vital electromyographic system for nerve monitoring during surgery.